The TRIPs Agreement and Pharmaceuticals. Report of an ASEAN Workshop on the TRIPs Agreement and its Impact on Pharmaceuticals. Jakarta, 2-4 May 2000
(2000; 91 pages) View the PDF document
Table of Contents
View the documentACKNOWLEDGEMENTS
View the documentLIST OF ABBREVIATIONS AND ACRONYMS
View the documentEXECUTIVE SUMMARY
View the documentI. INTRODUCTION
Close this folderII. GENERAL ISSUES
Open this folder and view contents2.1 Background
View the document2.2 WHO’s perspective on globalization and access to drugs
View the document2.3 The history of the TRIPs negotiations
Close this folder2.4 Stakeholders’ views
View the document2.4.1 The international innovative pharmaceutical industry’s perspective (IFPMA)
View the document2.4.2 A national pharmaceutical industry perspective (GP Farmasi, Indonesia)
View the document2.4.3 A consumer’s perspective (Consumers International)
Open this folder and view contents2.5 Country experiences
Open this folder and view contentsIII. TECHNICAL ISSUES
Open this folder and view contentsIV. SPECIAL ISSUES
View the documentV. ISSUES DISCUSSED IN WORKING GROUPS
View the documentVI. RECOMMENDATIONS
Open this folder and view contentsANNEXES
 

2.4 Stakeholders’ views

Three important stakeholders are the innovative pharmaceutical industry, the national pharmaceutical industry and the consumers. The views of representatives of these groups are presented in paragraphs 2.4.1 to 2.4.3.

to previous section
to next section
 
 
The WHO Essential Medicines and Health Products Information Portal was designed and is maintained by Human Info NGO. Last updated: October 7, 2014